MedTrace Logo

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

NCT01717391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-03-26

Study results available
· View outcomes & findings →

Summary

\[F-18\] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts. This would impact chemotherapy administration.

Conditions

  • Uterine Cervical Neoplasms
  • Endometrial Neoplasms
  • Anus Neoplasms
  • Rectal Neoplasms
  • Prostatic Neoplasms

Interventions

DRUG

fluorothymidine F 18

A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • John M. Buatti

    lead OTHER

Principal Investigators

  • John Buatti, PhD · Department of Radiation Oncology, The University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-01
Primary Completion
2016-02-29
Completion
2017-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717391 on ClinicalTrials.gov